1. Karami, J., Aslani, S., Ahmadreza J., Masoud Garshasbi, Mahdi M. 2019.

Genetic

Implications in the Pathogenesis of Rheumatoid Arthritis; an updated review. Gene. Vol.

702, 8-12

2. Lestari, 2014. Terapi Kompres Jahe dan Message Pada Osteoarthritis Sip Anti Wreda St.

Theresia Dharma Bakti Kasih Surakarta. Skripsi.

3. Owen, S. et al., 2012. MTHFRgene polymorphisms and outcomeof methotrexate

treatment in patients withrheumatoid arthritis: analysis of keypolymorphisms and meta-

analysis of C677Tand A1298C polymorphisms. Pharmacogenomics J, pp. 137 - 147

4. Song, G. G., Bae, S. C. & Lee, Y. H. 2014. Association of the MTHFR C677T and

A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-

analysis. Clin Rheumatol. 33, 1715–1724.

5. Y. H. Lee, S.-C. B. & Song, G. G. 2015. Association of the ABCB1 C3435T

polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis A

meta-analysis. Z Rheumatol, doi: 10.1007/s00393-00015-1618-x.

6. Romão, V. C., Lima, A., Bernardes, M., Canhão, H. & Fonseca, J. E. 2014. Three

decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity.

Immunol Res, 60, 289–310.

7. Malik, F. & Ranganathan, P. 2013. Methotrexate pharmacogenetics in rheumatoid

arthritis: a status report. Pharmacogenomics, 14, 305–314.

8. Verstappen, S. M. et al. 2010. Adverse events and factors associated with toxicity in

patients with early rheumatoid arthritis treated with methotrexate tight control therapy:

the CAMERA study. Ann Rheum Dis, 69, 1044–1048.

9. Zhu, H., Deng, F. Y., Mo, X. B., Qiu, Y. H. & Lei, S. F. 2014. Pharmacogenetics and

pharmacogenomics for rheumatoid arthritis responsiveness to methotrexate treatment: the

2013 update. Pharmacogenomics, 15, 551–566.

10. Ghodke-Puranik, Y. et al., 2015. Folate metabolic pathway single nucleotide

polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian

(Asian) patients with rheumatoid arthritis. Pharmacogenomics J, pp. 2019-2034.

11. Wessels, J. A. M. et al., 2006. Efficacy and Toxicity of Methotrexate inEarly Rheumatoid

Arthritis Are Associated WithSingle-Nucleotide Polymorphisms inGenes Coding for

Folate Pathway Enzymes. ARTHRITIS & RHEUMATISM, pp. 1087-1095.

12. Aurea Lima, J. M., Miguel Bernardes, H. S., Rita Azevedo, V. S. & Medeiros, R. 2014.

Prediction of Methotrexate Clinical Response in Portuguese Rheumatoid Arthritis

Patients: Implication of MTHFR rs1801133 and ATIC rs4673993 Polymorphisms.

Hindawi Publishing Corporation BioMed Research International 2014, Article ID

368681, 11 pages.

13. Chaabane, S. et al., 2015. Genetic Determinants of Methotrexate Toxicity in

TunisianPatients with Rheumatoid Arthritis: A Study of PolymorphismsInvolved in the

MTX Metabolic Pathway. Eur J Drug Metab Pharmacokinet.

14. Świerkot, J. et al., 2016. Associations between single-nucleotide polymorphisms of RFC-

1, GGH, MTHFR , TYMS, and TCII genesand the efficacy and toxicity of methotrexate
 treatment in patients with rheumatoid arthritis. POLSKIE ARCHIWUM MEDYCYNY

WEWNĘTRZNEJ, pp. 152 - 161.

15. Lima, A. et al., 2014. Prediction of Methotrexate Clinical Response inPortuguese

Rheumatoid Arthritis Patients: Implication ofMTHFRrs1801133 andATICrs4673993

Polymorphisms. BioMed Research International.

16. Brambila-Tapia, et al. 2012. MTHFR C677T, MTHFR A1298C, and OPG A163G

Polymorphisms in Mexican Patients with Rheumatoid Arthritis and Osteoporosis.

Disease Markers. 109 – 114

17. Kato, et al., 2012. Genetic polymorphisms in metabolic andcellular transport pathway of

methotrexate impact clinical outcome ofmethotrexate monotherapy in Japanese patients

with rheumatoid arthritis.. Drug Metab Pharmacokinet., p. 192–199.

18. Choe, J.-Y.et al., 2012. Methylenetetrahydrofolate reductase polymorphisms, C677T and

A1298C, areassociated with methotrexate-related toxicities in Korean patients with

rheumatoid arthritis.. Rheumatol Int.

19. Tasbas, Ö. et al., 2011. The Frequency of A1298C and C677T Polymorphisms of the

Methylentetrahydrofolate Gene in Turkish Patients with Rheumatoid Arthritis:

Relationship with Methotrexate Toxicity. Rheumatology Journal, pp. 30 - 35.

20. Gonzalez-Mercado, G. et al., 2017. MTRRA66G,RFC1G80A, andMTHFRC677Tand

A1298C Polymorphisms and Disease Activity in Mexicans with Rheumatoid

ArthritisTreated with Methotrexate. GENETIC TESTING AND MOLECULAR

BIOMARKERS, pp. 698 – 704.

21. Lee, Y. H. & Bae, S. C. 2016. Association of the ATIC 347 C/G polymorphism with

responsiveness to and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis.

Rheumatol Int, doi: 10.1007/s00296-00016-3523-2

22. Lima A, Azevedo R, Sousa H, Seabra V, Medeiros R (2013)Current approaches for

TYMS polymorphisms and their impor-tance in molecular epidemiology and

pharmacogenetics.Pharmacogenomics 14:1337–1351

23. Wessels, J. A. et al. 2007. A clinical pharmacogenetic model to predict the efficacy of

methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum56,

1765–1775.

24. Lima, A. et al. 2014. Role of key TYMS polymorphisms on methotrexate therapeutic

outcome in portuguese rheumatoid arthritis patients. PLoS One9, e108165

25. Jekic, B. et al. Association of the TYMS 3G/3G genotype with poor response and GGH

354GG genotype with the bone marrow toxicity of the methotrexate in RA patients. Eur J

Clin Pharmacol69, 377–383 (2013)

26. James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LGet al. 2008. Common

polymorphisms in the folate pathway predictefficacy of combination regimens containing

methotrexate andsulfasalazine in early rheumatoid arthritis. J Rheumatol 35:562–571

27. Świerkot J,Ślęzak R, KarpińskiP,Pawłowska J, Noga L,Szechiński J et al. 2015.

Associations between single-nucleotidepolymorphisms of RFC-1, GGH, MTHFR,

TYMS, and TCII genesand the efficacy and toxicity of methotrexate treatment in

patientswith rheumatoid arthritis. Pol Arch Med Wewnętrznej 125:152–161

28. Bohanec Grabar P, Logar D, Lestan B, Dolzan V. 2008. Geneticdeterminants of

methotrexate toxicity in rheumatoid arthritis pa-tients: a study of polymorphisms

affecting methotrexate transportand folate metabolism. Eur J Clin Pharmacol 64:1057–

1068

29. Nikbakht M., MalekZadeh K., Kumar Jha A., Askari M., Marwaha R. K., Kaul D., et al.

(2012). Polymorphisms of MTHFR and MTR genes are not related to susceptibility to

childhood ALL in north india. Exp. Oncol. 3443–48.

30. Jacques P. F., Bostom A. G., Selhub J., Rich S., Ellison R. C., Eckfeldt J. H., et al.

(2003). Effects of polymorphisms of methionine synthase and methionine synthase

reductase on total plasma homocysteine in the NHLBI family heart study.

Atherosclerosis 166 49–55

31. SHEN Shi-hua, X. U. J., XU Sheng-qian, L. L. & L. I. Ying-wei, X. H. The relationship

between the single nucleotide polymorphism of MTR, MTRR gene and the treatmentof

methotrexate in rheumatoid arthriti. Chinese Pharmacological Bulletin25, 1068–1071

(2009)